Nootropics Index - Save on smarter supplements
Nootropics>Synthetic nootropics & research compounds>PRL-8-53
Synthetic nootropics & research compounds

PRL-8-53

PRL-8-53 hydrochloride

PRL-8-53 is a synthetic research nootropic with a limited historical memory signal. Human evidence comes mainly from a small 1978 experiment; it does not establish routine use, a daily dose or long-term safety. Compare the stated chemical form and total declared compound mass when checking capsule and powder offers.

Memory SupportSyntheticClinical ResearchLimited Human EvidencePregnancy CautionMedication Interaction RiskLong Term Safety Unknown
Updated October 2026/5 min read/5 citations
Reviewed by the NootropicsIndex editorial team.Method: prioritize cited human research and official safety or regulatory sources; compare retailer-listed prices without endorsing products.Affiliate disclosure
01

What is it?

Limited evidence for routine use2
The safety rating on this page describes the absence of reported harm in a brief historical experiment. Confidence is low: current products, repeated dosing and long-term use do not have an established safety profile. A low observed short-term harm signal is not a clearance for human use.

What the memory finding can support

2

A laboratory word-retention result is narrower than better focus, intelligence or productivity. The public evidence supports a research signal, not a reliable study aid or a predictable gain for every user.

02

Names, aliases and forms

Research CodePRL-8-53
Spelling VariantPRL 8-53
Salt FormPRL-8-53 hydrochloride
Chemical NameMethyl 3-(2-(benzyl(methyl)amino)ethyl)benzoate hydrochloride
Cas Number51352-87-5
Molecular FormulaC18H22ClNO2
InchikeyHLBBSWSJLPLPRU-UHFFFAOYSA-N
03

Mechanisms of action

Mechanism claims remain provisional

2

Descriptions of dopamine, serotonin and cholinergic effects largely trace to historical animal work. These do not establish the human mechanism or predict a useful medication stack.

04

Potential effects and evidence map

Grade C: one small double-blind human experiment reported improved verbal retention, with little improvement in learning and no significant change in visual reaction time or motor control. Independent replication was not identified in the literature search completed on 14 October 2026. Real-world productivity benefits remain unproven.

Effect domainMagnitudeGrade
Memory / learning2
AcuteConfidence: Low

A historical verbal-retention signal; everyday memory benefits remain unconfirmed.

Note Small study, subgroup analyses, variable endpoint samples and no identified independent replication. A score of 1 describes weak potential, not a measured effect size.

1/5
C
Focus / attention2
UnknownConfidence: Low

A useful focus or productivity benefit is not established.

Note Visual reaction-time testing does not establish sustained attention, exam performance or work output.

0/5
E
05

Typical dosages and timing

Oral study dose25 mg

The experiment enrolled 47 healthy adult volunteers. This is a per-administration study amount; it does not establish a daily intake range, a dose-response curve or a safe repeated-use schedule. Retailer serving sizes are separate label claims.

06

Timing & effect horizon

Effect horizonAcute
Acute
Study test interval2Acute
2-2.5 hours
Testing time is not onset2

The featured interval is the gap between oral administration and the laboratory task. It is not a measured onset or peak. Later recall tests measured retention of learned words, not continuous drug action. Human The time for blood levels to fall by half during the final elimination phase.Source, practical effect duration and an evidence-based cycle remain unresolved.

07

Safety, side effects and risk profile

Special populations lack evidence2
The evidence reviewed does not establish safety in pregnancy or breastfeeding, adolescents, or people with major medical conditions. These are population-specific evidence gaps, not demonstrated PRL-8-53 adverse effects and not the basis of the healthy-adult base rating.
Evidence uncertainty2
Confidence: Low

The small experiment reported no adverse reactions. Uncommon or delayed harms cannot be estimated from that observation.

Note Base rating is narrowly anchored to the historical low-dose oral study in healthy adults. Minimal observed short-term concern is not proof of safety for current products or repeated use. Uncertainty is not evidence of severe toxicity.

1/5
C
What the safety rating means2

Minimal, 1/5, is a low-confidence rating for recorded short-term harm in the historical oral study. A higher intrinsic-risk label would need a credible harm signal; sparse data, legal status and product-quality concerns alone do not establish one. This study cannot determine rare-event likelihood, repeat-use risk, dependence or delayed toxicity.

08

Interactions and cautions

Medication combinations are uncharacterized2

The reviewed evidence does not establish interaction safety with prescriptions, stimulants, sedatives, alcohol or other nootropics. Animal neurotransmitter findings are not a dosing or stacking guide. No specific clinical interaction is asserted here.

09

Legal and regulatory status

United States: an identifier is not approval3

As of 14 October 2026, FDA’s substance registry lists PRL-8-53 free base and states that a UNII identifier does not imply regulatory review or approval. Registry inclusion or an online offer does not establish authorization for human use. This page makes no compound-specific determination about U.S. sale, import or possession; other jurisdictions require separate checks.

10

How it compares

Chemical form3

This profile describes the hydrochloride salt: CAS 51352-87-5. FDA’s separately identified free base has CAS 51352-88-6. Do not assume products using the broad name have the same salt form or compare their declared mass as interchangeable. No relative-bioavailability advantage is established here.

11

Practical buying and quality notes

  • For a label stating 10 mg per capsule and 60 capsules, the total declared compound mass is 600 mg. A powder bottle labelled 500 mg is a different total quantity. Price per capsule and price per gram cannot be compared directly. Use the same stated chemical form and declared mass, then account for shipping, region and freshness; these calculations do not verify contents or imply a serving recommendation.4
  • Check that any certificate of analysis matches the batch and identifies the chemical form, assay method and what was tested. A purity percentage is not a per-capsule content result, and neither a certificate nor a retailer label establishes efficacy or long-term safety. Keep declared amount, verified content and evidence of benefit separate.4
12

FAQ

What PRL-8-53 dosage is supported by research?

2

The historical oral amount appears in the study-dose section above. No validated daily dosage or dose-response range was identified. A retailer serving size does not extend the study evidence.

How long does PRL-8-53 last, and is cycling supported?

2

The available human evidence does not establish an effect-duration window, human half-life or useful cycle. A recall measurement taken later is not proof that the compound remains active until that test.

Does a lower listed price mean a better PRL-8-53 product?

4

Compare like-for-like chemical form and declared mass before ranking prices. Capsule count, total powder mass, shipping and documentation answer different questions. A lower price does not establish quality or suitability for human use.

13

References

  1. PubChem Compound Summary for CID 70700868, PRL-8-53 hydrochloride.
  2. Hansl NR, Mead BT. PRL-8-53: enhanced learning and subsequent retention in humans as a result of low oral doses of new psychotropic agent. Psychopharmacology. 1978;56(3):249-253.
  3. U.S. FDA. Substance Registration System: PRL-8-53 free base, UNII BM2TE2XHK6. Accessed 14 October 2026.
  4. U.S. FDA. Questions and Answers on Dietary Supplements. Accessed 14 October 2026.
  5. Napoletano F et al. The Psychonauts’ World of Cognitive Enhancers. Front Psychiatry. 2020;11:546796.
Note

This page is informational and summarizes available evidence. It is not medical advice, a recommendation, or a substitute for guidance from a qualified clinician.